Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07653139 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany

StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Oct 26, 2026 → Dec 26, 2026
See other at-risk trials from Novo Nordisk

Record History

  1. Enrolling by invitation only Lead sponsor: Novo Nordisk A/S to Novo Nordisk A/S · Primary and study completion pushed from Oct 26, 2026 to Dec 26, 2026 · Start date changed from estimate of Jul 10, 2026 to Sep 25, 2026 · 1 more Show 4 more changesShow less
    • Lead sponsor: Novo Nordisk A/S to Novo Nordisk A/S
    • Primary and study completion pushed from Oct 26, 2026 to Dec 26, 2026
    • Start date changed from estimate of Jul 10, 2026 to Sep 25, 2026
    • Eligibility criteria expanded, about 10 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novo Nordisk
268 trials monitored
See 15 trials at risk
Hemophilia
236 trials monitored
See 12 trials at risk
This study aims to generate structured patient preference evidence on prophylactic treatment options for haemophilia A for adults with and without inhibitors to support health technology assessment and benefit evaluation processes. The study will examine how individuals with haemophilia A evaluate trade-offs between treatment effectiveness, safety, and treatment administration characteristics when choosing between prophylactic therapies. Participants will repeatedly choose between hypothetical treatment profiles that differ in clinically relevant attributes and levels.
Trial Details
NCT Number NCT07653139
Lead Sponsor Novo Nordisk A/S
Conditions Haemophilia A
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov